Tretinoin ( DrugBank: Tretinoin )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
62	発作性夜間ヘモグロビン尿症	1
75	クッシング病	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00919555 (ClinicalTrials.gov)	June 2008	8/6/2009	Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)	Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Pioglitazone and Tretinoin;Drug: Tretinoin and Pioglitazone HCL;Drug: Placebo	Phoenix Neurological Associates, LTD	NULL	Completed	18 Years	85 Years	Both	28	Phase 1/Phase 2	United States

62. 発作性夜間ヘモグロビン尿症

---

臨床試験数 : 292 /  薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000039675	2021-01-01	2020-11-05	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria	paroxysmal nocturnal hemoglobinuria	experimental group:Tretinoin 0.33mg/kg.d; methylprednisolone 0.8mg/kg.d;Control test:methylprednisolone 0.8mg/kg.d;	Department of Hematology, Second Medical Center, Chinese PLA General Hospital	NULL	Recruiting	14	80	Both	experimental group:10;Control test:10;	Phase 2	Chinese

75. クッシング病

---

臨床試験数 : 205 /  薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cushing's disease.	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study. - CRACCA	Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient. MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA Other descriptive name: NON COMMERCIAL Trade Name: VESANOID Product Name: Tretinoina Product Code: [L01XX14] INN or Proposed INN: TRETINOINA Other descriptive name: NON COMMERCIAL	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
2	EUCTR2008-006379-65-IT (EUCTR)	27/10/2008	12/11/2008	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease	sperimentation only in patients	INN or Proposed INN: Tretinoin	ISTITUTO AUXOLOGICO ITALIANO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy